Table 2.
Characteristics of subjects who received radioactive iodine for differentiated thyroid cancer, stratified by nationality as Lebanese versus non-Lebanese.
| Nationality | p value | ||
|---|---|---|---|
| Lebanese N = 118 | Non-Lebanese N = 56 | ||
| Gender n (%) | |||
| Male | 31 (26.3) | 19 (33.9) | 0.30 |
| Female | 87 (73.7) | 37 (66.1) | |
| Age, mean (±SD) | 44.2 ± 15.2 | 39.8 ± 12.2 | 0.06 |
| BMI, mean (±SD) | 27.4 ± 5.2 | 30.9 ± 7.6 | 0.004 |
| SBP, mean (±SD) | 123.5 ± 15.3 | 128.6 ± 16.4 | 0.05 |
| DBP, mean (±SD) | 78.1 ± 11.5 | 82.2 ± 11.8 | 0.03 |
| Tumor pathology n (%) | |||
| PTC | 108 (91.5) | 54 (96.4) | 0.42 |
| FTC | 8 (6.8) | 2 (3.6) | |
| Other | 2 (1.7) | 0 (0.0) | |
| Recurrence, yes n (%) | 17 (14.4) | 9 (16.1) | 0.77 |
| Lymph node, yes n (%) | 54 (56.8) | 35 (81.4) | 0.005 |
| RAI dose n (%) | |||
| 50 mCi | 30 (25.4) | 10 (17.9) | 0.38 |
| 100 mCi | 74 (62.7) | 36 (64.3) | |
| 150 mCi | 14 (11.9) | 10 (17.9) | |
| Thyrogen, yes | 4 (3.4) | 3 (5.5) | 0.68 |
| Pretherapy TSH (mIU/L) mean (±SD) | 85.0 ± 22.2 | 81.5 ± 25.9 | 0.39 |
| Pretherapy TSH (mIU/L)–categorical∗ | |||
| <50 | 9 (8.2) | 9 (16.7) | 0.25 |
| 50–75 | 18 (16.4) | 9 (16.7) | |
| >75 | 83 (75.5) | 36 (66.7) | |
| Smoking, yes n (%) | 32 (27.4) | 7 (12.5) | 0.03 |
| Alcohol, yes n (%) | 21 (17.8) | 2 (3.6) | 0.01 |
| Dental problems, yes n (%) | 2 (2.1) | 1 (2.3) | 1.00 |
| Days off LT4, mean (±SD) | 20.6 ± 16.1 | 37.1 ± 20.8 | 0.02 |
| Days after surgery, mean (±SD) | 40.3 ± 28.1 | 47.5 ± 56.3 | 0.45 |
| Days off total, mean (±SD) | 37.2 ± 27.5 | 45.2 ± 50.7 | 0.19 |
| WBS result∗∗n (%) | |||
| Negative | 12 (13.0) | 7 (20.0) | 0.31 |
| Positive | 71 (77.2) | 27 (77.1) | |
| Distant | 9 (9.8) | 1 (2.9) | |
| Treatment received n (%) | |||
| NSAIDs | 11 (9.3) | 9 (16.1) | 0.60 |
| Steroids | 3 (2.5) | 2 (3.6) | |
| Both | 2 (1.7) | 4 (8.9) | |
∗10 patients did not have TSH levels available; ∗∗47 patients did not have WBS results available.